Featuring:

RNAi therapeutics for neurodegenerative disease: challenges and prospects
Matthew JA Wood, Department of Physiology, Anatomy and Genetics, University of Oxford

Night on Highway 128
Dr.Kary Mullis

The role of chemokines in type 1 diabetes: as assessed by RT-PCR
Lut Overbergh, Senior postdoctoral fellow et al, Catholic University of Leuven

Antibody based proteomics to study cellular signalling networks
Jan van Oostrum, Head of Business Development, Zeptosens, Hans Voshol, Group Leader Protein Sciences, Novartis Institutes for Biomedical Research

Personalised Medicine: are we ready for the revolution?
Claudio Carini, F. M.D., Ph.D., FRCPath, F. VP of TM at MDS Pharma and Candida Fratazzi M.D., Senior Director, Altus Pharma

High Content Screening as improved lead finding strategy
Marjo Simonen and Daniela Gabriel, Novartis Institutes for Biomedical Research, Basel

Going paperless: is now the time?
John Trigg, Director, PhaseFour Informatics

IDBS: Integrated framework
Neil Kipling, Chairman and CEO, IDBS

Test method validation for cleaning validation samples
Richard Forsyth, Associate Director in Worldwide GMP Quality, Merck & Co., Inc

Thermal analysis and calorimetry: latest developments
Danielle Giron, Chemical Research & Development, Novartis Pharma AG, Basel, Switzerland

PAT: not a purpose in itself
Peter Van Broeck, Tom Van den Kerkhof, Mario Hellings and Koen De Smet, Johnson & Johnson